Literature DB >> 15279577

Advanced preclinical and clinical trials of natural products and related compounds from marine sources.

David J Newman1, Gordon M Cragg.   

Abstract

The marine environment has proven to be a very rich source of extremely potent compounds that have demonstrated significant activities in anti-tumor, anti-inflammatory, analgesia, immuno-modulation, allergy and anti-viral assays. Although the case can and has been made that the nucleosides such as Ara-A and Ara-C are derived from knowledge gained from investigations of bioactive marine nucleosides, no drug directly from marine sources (whether isolated or by total synthesis) has yet made it to the commercial sector in any human disease. However, as shown in this review, there are now significant numbers of very interesting molecules that have come from marine sources, or have been synthesized as a result of knowledge gained from a prototypical compound, that are either in or approaching Phase III clinical trials in cancer, analgesia and allergy, with a very substantial number of other, quite different potential agents following in their wake, in these and in other diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279577     DOI: 10.2174/0929867043364982

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  38 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  An integrated control strategy for the fermentation of the marine-derived fungus Aspergillus glaucus for the production of anti-cancer polyketide.

Authors:  Menghao Cai; Xiangshan Zhou; Jian Lu; Weimin Fan; Jiushun Zhou; Chuanpeng Niu; Li Kang; Xueqian Sun; Yuanxing Zhang
Journal:  Mar Biotechnol (NY)       Date:  2012-12       Impact factor: 3.619

3.  Drug discovery from natural sources.

Authors:  Young-Won Chin; Marcy J Balunas; Hee Byung Chai; A Douglas Kinghorn
Journal:  AAPS J       Date:  2006-04-14       Impact factor: 4.009

4.  Statistical optimization of medium composition for aspergiolide A production by marine-derived fungus Aspergillus glaucus.

Authors:  Meng-Hao Cai; Xiang-Shan Zhou; Xue-Qian Sun; Ke-Jing Tao; Yuan-Xing Zhang
Journal:  J Ind Microbiol Biotechnol       Date:  2008-12-23       Impact factor: 3.346

5.  Phenotypic and genomic characterization of the Antarctic bacterium Gillisia sp. CAL575, a producer of antimicrobial compounds.

Authors:  Isabel Maida; Marco Fondi; Maria Cristiana Papaleo; Elena Perrin; Valerio Orlandini; Giovanni Emiliani; Donatella de Pascale; Ermenegilda Parrilli; Maria Luisa Tutino; Luigi Michaud; Angelina Lo Giudice; Riccardo Romoli; Gianluca Bartolucci; Renato Fani
Journal:  Extremophiles       Date:  2013-10-23       Impact factor: 2.395

Review 6.  Bioactive Compounds from Marine Heterobranchs.

Authors:  Conxita Avila; Carlos Angulo-Preckler
Journal:  Mar Drugs       Date:  2020-12-21       Impact factor: 5.118

7.  Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells.

Authors:  C B Pollock; H Koltai; Y Kapulnik; C Prandi; R I Yarden
Journal:  Breast Cancer Res Treat       Date:  2012-03-29       Impact factor: 4.872

8.  Quorum sensing antagonism from marine organisms.

Authors:  Mette Elena Skindersoe; Piers Ettinger-Epstein; Thomas Bovbjerg Rasmussen; Thomas Bjarnsholt; Rocky de Nys; Michael Givskov
Journal:  Mar Biotechnol (NY)       Date:  2007-10-20       Impact factor: 3.619

Review 9.  Recent synthetic studies leading to structural revisions of marine natural products.

Authors:  Yoshihide Usami
Journal:  Mar Drugs       Date:  2009-07-13       Impact factor: 5.118

Review 10.  Mediterranean jellyfish venoms: a review on scyphomedusae.

Authors:  Gian Luigi Mariottini; Luigi Pane
Journal:  Mar Drugs       Date:  2010-04-04       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.